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Abstract
Background: There is discordance among studies assessing the impact of race on outcome of patients with Triple Negative Breast 
Cancer (TNBC). We assessed survival outcomes for African American (AA) versus Caucasian (CA) women with TNBC treated at an 
urban cancer center in Memphis, TN with a predominant AA patient population.
Methods: Patients with Stage I-III TNBC were identified from our breast database. Event free survival (EFS) and Breast cancer specific 
survival (BCSS) were the primary outcome measures. Cox proportional hazards models were fitted for EFS and BCSS.
Results: Of the 124 patients, 71% were AA. No significant association between race and stage (P = 0.21) or menopausal status 
(P = 0.15) was observed. Median age at diagnosis was significantly lower for AA versus CA women (49.5 vs. 55 years, P = 0.024). 
92% of the patients received standard neo/adjuvant chemotherapy, with no significant difference in duration and type of chemotherapy 
between the races. With a median follow up of 23 months, 28% of AA vs. 19% of CA women had an event (P = 0.37). 3 year EFS and 
BCSS trended favorably towards CA race (77% vs. 64%, log rank P = 0.20 and 92% vs. 76%, P = 0.13 respectively) with a similar trend 
noted on multiple   variable modeling (EFS: HR 0.62, P = 0.29; BCSS: HR 0.36, P = 0.18). AA women $50 years at diagnosis had a 
significantly worse BCSS than the CA women in that age group (P = 0.012).
Conclusion: Older AA women with TNBC have a significantly worse breast cancer specific survival than their CA counterparts. 
  Overall, there is a trend towards lower survival for AA women compared to Caucasians despite uniformity of tumor phenotype and 
treatment. The high early event rate, irrespective of race, underscores the need for effective therapies for women with TNBC.
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Triple negative breast cancer (TNBC) is character-
ized by a lack of histologic expression of   estrogen 
and    progesterone  receptors  and  HER2  protein 
on the   surface of tumor cells (ER, PR and HER2 
  negative). TNBC is more likely to have aggressive 
  clinicopathologic features like a higher nuclear and 
histologic  grade,  higher  mitotic  index,  advanced 
stage,  and  a  younger  age  at  presentation.1,2  By 
gene   expression analysis, a majority of the TNBCs 
  cluster with the “basal-like” tumors, which have a 
worse prognosis compared to the hormone   receptor 
  positive  subgroups  (luminal A  and    luminal  B).3,4 
There is a debate in literature,   however, as to the 
true  biologic  origin  of  these  tumors  and  they 
likely   constitute a more heterogeneous group than 
  presently    recognized.5  Epidemiological    studies 
show  the    highest  prevalence  of  TNBC  among 
  African   American (AA) women, especially younger 
premenopausal African Americans.1,6 This may, in 
part, explain a higher mortality rate despite a lower 
incidence of breast cancer overall among African 
Americans, though other factors like   socioeconomic, 
cultural and treatment differences have been linked 
to this disparity as well.7–10 This racial disparity in 
  survival,  however,  persists  after  adjustment  for 
  treatment distribution and access to health care.11,12
There  are  limited  reports  in  literature  that  spe-
cifically  address  the  question  of  whether    African 
  American  race  independently  confers  a  worse 
  outcome in patients with a triple negative   phenotype. 
Two  population  based  studies  have  shown  worse 
  survival   associated with AA race for patients with 
  triple    negative  tumors.13,14  Contrary  to  that,  in  a 
cohort  of  patients  with  TNBC  treated  uniformly 
with   pre-operative chemotherapy at a tertiary cancer 
  center, an   independent effect of race on survival was 
not observed after adjustment for other variables.15
We aimed to examine the association between race 
and survival outcomes of women with TNBC who 
were treated at the University of Tennessee Cancer 
Institute. Our institution caters to a large inner city 
population  with  a  predominant  African  American 
representation. We analyzed any association between 
race and specific tumor and treatment characteristics 
for this cohort of patients. This report summarizes our 
findings.
patients and Methods
All female patients with a diagnosis of invasive breast 
cancer treated at the University of   Tennessee Cancer 
Institute,  Memphis,  between  September  2003  and 
December  2008  were  screened  by  a  search  of  our 
  electronic medical record system. Patients who had 
ER, PR and HER2 negative tumors were   identified. 
  Pathology  reports  were  reviewed  to    confirm    triple 
  negative  status  of  the  tumors.  ER  and  PR  were 
  considered as negative if the percentage of cells   staining 
positive by   immunohistochemistry (IHC) were below 
the minimum cut-off required for a positive result by 
the manufacturer’s standard. A documented absence 
of HER2 gene amplification by fluorescence in situ 
hybridization was required in case of 2+   staining by 
IHC. Patients were excluded if their race was reported 
as other than AA or   Caucasian, if they had incomplete 
information for stage at   presentation and receptor status, 
had stage IV   disease at   presentation, did not undergo 
definitive breast   surgery, or were lost to follow up prior 
to   initiation of any therapy for breast cancer.   Individual 
patient    medical  records  were  reviewed  to  collect 
  demographic, clinical and treatment information.
Information  on  the  following  variables  was 
recorded: patient characteristics including race, age 
at diagnosis and menopausal status; tumor character-
istics   including tumor size, modified Scarff-Bloom-
Richardson grade, stage at   diagnosis according to the 
AJCC staging   criteria, sixth   edition (2002); treatment 
details   including receipt or non receipt of chemother-
apy in the adjuvant or   neo-  adjuvant setting, duration 
and type of   chemotherapy received, type and date 
of   definitive surgery, details of axillary staging, and 
receipt of adjuvant radiation therapy. The study was 
approved by the Institutional Review Board at the 
University of Tennessee Health Science Center.
statistical Analysis
Survival  Outcome  measures  for  this  analysis  were 
Event Free Survival (EFS) and Breast Cancer   Specific 
Survival (BCSS) for the whole cohort and separately 
for AA and Caucasian patients. EFS was measured from 
the date of definitive breast cancer surgery to the date of 
first recurrence (locoregional,   contralateral or   distant) 
or death from breast cancer, whichever occurred first. 
BCSS was measured from the date of definitive breast 
cancer surgery to the date of death from breast cancer. 
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censored  at  the  date  of  the  last    follow  up  for  this 
analysis. Patients who had no evidence of recurrence 
of breast cancer prior to death were also censored at 
the date of last follow up. Survival   estimates for the 
entire cohort and for the two races were obtained by 
the Kaplan-Meier method and the log rank test was 
employed for comparing the survival curves.
We  investigated  associations  between  race  and 
patient, tumor and treatment variables using   Fisher’s 
exact test. Differences in the medians between two 
groups  of  continuous  variables  were  tested  by  the 
  Wilcoxon-Mann-Whitney test. Cox proportional haz-
ards models were fitted separately for EFS and BCSS 
to determine the relationship of patient, tumor and 
treatment variables with survival outcomes.   Variables 
that attained a significance level of 0.15 in the uni-
variate models were considered for   inclusion in the 
multiple variable models. The best multiple variable 
models for each outcome were chosen by step-wise 
selection. Race was included in all   models, regardless 
of significance, because our primary   objective was to 
determine the influence of race on survival outcomes. 
A  P-value ,0.05 was considered significant in the 
final multiple variable models for both survival out-
comes. Due to the retrospective nature of this study, 
sample size was limited and no power calculations 
were made. All analyses were   performed using SAS 
Version 9.2.
Results
Patient characteristics
Between  September  2003  and  December  2008, 
147 patients with a diagnosis of triple negative breast 
cancer were referred to the University of Tennessee 
Cancer Institute. Twenty three patients were excluded 
from this analysis because they met one or more of the 
exclusion criteria described under the methods   section: 
13 with stage IV disease, 2 with race other than AA 
or Caucasian, 2 with incomplete staging information, 
3 who progressed to stage IV disease prior to   definitive 
surgery,  1  patient  with  a  squamous  cell  histology, 
and 2 lost to follow up immediately after definitive 
  surgery. Table 1 summarizes the   characteristics of the 
124 patients included in this report.
Of the 124 patients, 71% were AA. The median 
age at diagnosis for the whole cohort was 51 years 
(range 26–82 years). There was a trend towards a 
greater proportion of AA women diagnosed at age 
younger than 50 as compared to Caucasians (50% vs. 
31%, Fisher’s exact P value = 0.07). Median age at 
diagnosis for AA women was significantly lower than 
the Caucasian women {49.5 years (range 28–77) vs. 
55 years (range 26–82), P value = 0.024}. There was 
no significant association between menopausal status 
and race (P value = 0.15). Stage at presentation did 
not differ by race (P value = 0.21).
Neoadjuvant/Adjuvant Treatment
Of the 124 patients, 114 (92%) and 79 (66%) received 
adjuvant chemotherapy and radiotherapy   respectively. 
There was no difference in the proportion of patients 
who received neoadjuvant/adjuvant therapy by race 
(Table  1).  The  median  number  of  chemotherapy 
cycles was 7 (range 0–10), and did not differ by race 
(Wilcoxon Mann Whitney test P value = 0.68).
The  proportion  of  patients  who  received  both 
anthracyclines and taxanes as part of their chemother-
apy regimen was not significantly different between 
the races (65% of AA patients versus 56% of CA 
patients, Chi- square P value = 0.36).
Survival results
With a median follow up of 23 months (range 1–124 
months), 32 patients (26%) have had a breast   cancer 
event, i.e. recurrence or death related to breast   cancer 
(Table 2). The site of first relapse i.e.   locoregional 
(LR) versus systemic ± locoregional (LRS) did not 
differ  by  race. The  overall  3  year  EFS  and  BCSS 
estimates  for  the  cohort  were  68%  (SE,  5%)  and 
81% (SE, 5%) respectively. The three-year EFS and 
BCSS  estimates  for AA  race  were  64%  and  76% 
  respectively.  The    corresponding  3-  year  EFS  and 
BCSS estimates for Caucasians were 77% and 92% 
respectively (Table 3). Figures 1a and 1b illustrate the 
Kaplan-Meier   survival curves with the   corresponding 
log-rank P-  values for EFS and BCSS. Though the dif-
ference in   survival between the two races did not reach 
statistical   significance, both the unadjusted and stage 
adjusted s  urvival (Figs. 2a and 2b) trend towards a 
better   outcome for the Caucasian patients. When ana-
lyzed by age at   diagnosis (,50 vs. $50), among the 
patients in the older age group, BCSS was   significantly 
lower for AA patients compared to the CA patients 
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tistically significant survival   difference noted between 
the races among the younger patients (Fig. 3a).
Cox proportional hazard modeling
The following variables were included in the univari-
ate models for EFS and BCSS: race (  Caucasian vs. 
AA), lymph node status (positive vs. negative), stage 
at presentation (III vs. I or II), tumor grade (3 vs. 
1 & 2), menopausal status (pre vs. post   menopausal), 
age  at  diagnosis  ($50  vs.  ,50),  adjuvant  radia-
tion  (not  received  vs.  received),    adjuvant  chemo-
therapy (received vs. not received), and the type of 
  surgery (mastectomy vs. segmental   resection). Only 
Table 1. Patient characteristics.
characteristic* AA 
n = 88 (71%)
caucasian 
n = 36 (29%)
Total 
n = 124 (100%)
P-value
Age groups 
,50 
$50
 
44 (50) 
44 (50)
 
11 (31) 
25 (69)
 
55 (44) 
69 (56)
 
0.07
Menopausal status 
Post 
Pre
 
53 (60) 
35 (40)
 
27 (75) 
9 (25)
 
80 (65) 
44 (35)
 
0.15
nodal status 
Negative 
Positive
 
41 (47) 
46 (53)
 
23 (64) 
13 (36)
 
64 (52) 
59 (48)
 
0.11
stage 
i 
ii 
iii
 
18 (21) 
53 (61) 
16 (18)
 
12 (33) 
16 (45) 
8 (22)
 
30 (24) 
69 (56) 
24 (20)
 
0.21
Grade 
i/ii 
iii
 
9 (11) 
73 (89)
 
4 (12) 
30 (88)
 
13 (11) 
103 (89)
 
0.99
surgery 
Mastectomy 
Lumpectomy
 
41 (47) 
47 (53)
 
22 (61) 
14 (39)
 
63 (51) 
61 (49)
 
0.17
neo/Adjuvant  
chemotherapy 
Yes 
No
 
80 (91) 
8 (9)
 
34 (94) 
2 (6)
 
114 (92) 
10 (8)
 
0.7
Adjuvant  
radiotherapy 
Yes 
No
 
57 (65) 
31 (35) 
 
24 (67) 
12 (33)
 
79 (66) 
41 (34)
 
0.99
*Due to missing data, the numbers for some of the baseline characteristics do not add up to the column totals.
Table 2. Patient outcomes.
Outcome measure AA 
n = 88 (71%)
caucasian 
n = 36 (29%)
Total 
n = 124 (100%)
P-value*
Breast cancer event 
Yes 
No
 
25 (28) 
63 (72)
 
7 (19) 
29 (81)
 
32 (26) 
92 (74)
 
0.37*
Breast cancer death 
Yes 
No
 
12 (14) 
76 (86)
 
2 (6) 
34 (94)
 
14 (11) 
110 (89)
 
0.35*
site of 1st relapse 
LR 
LRS
 
10 (40) 
15 (60)
 
2 (29) 
5 (71)
 
12 (38) 
20 (63)
 
0.68*
*Fisher’s exact P values.
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Figure 1b. BCSS by race, P = 0.13.
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Figure 2a. Stage adjusted EFS by race. Stage i/ii CA vs. AA P = 0.25; Stage iii CA vs. AA P = 0.18.
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Figure 2b. Stage adjusted BCSS by race. Stage i/ii CA vs. AA P = 0.56; Stage iii CA vs. AA P = 0.22.
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AA caucasian Overall P-value**
3 year eFs, % (se) 
Node negative 
Node positive
64 (7) 
73 (10) 
53 (9)
77 (8) 
79 (10) 
75 (13)
68 (5) 0.20 
0.97 
0.19
3 year Bcss, % (se) 
Node negative 
Node positive
76 (6) 
89 (7) 
70 (9)
92 (6) 
91 (9) 
92 (8)
81 (5) 0.13 
0.95 
0.15
**Log rank P values comparing the entire survival curves between groups.
the   variables that were retained in the final   multiple 
  variable  models  for  EFS  and  BCSS  are  shown  in 
Table 4. After controlling for other variables, though 
not  statistically  significant  the  survival  outcomes 
trended in favor of the Caucasian race for both EFS 
(HR 0.62, P = 0.29) and BCSS (HR 0.36, P = 0.18). 
Stage  at  presentation  retained  significance  after 
adjustment for other   variables in the final models for 
both EFS and BCSS.
Discussion
TNBC  represents  a  biologically  distinct  subset  of 
breast cancer, with high chemotherapy responsiveness, 
but paradoxically poor long term survival with the 
greatest hazard of recurrence during the first 2–3 years 
after diagnosis.16 That over a quarter of our patients 
had a breast cancer event with a median   follow up of 
23 months, underscores the distinct natural history of 
TNBC as compared to the luminal subtypes where 
a  continued  hazard  of  recurrence  is  observed  even 
beyond the first 5 years after diagnosis.17
There is an association between African ancestry 
and the likelihood of developing a tumor with a 
triple negative phenotype. Non African American 
black women have also been found to have a higher 
  prevalence of TNBC, a younger age at diagnosis 
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Figure 3a. Age adjusted EFS by race. Age , 50 years CA vs. AA P = 0.53; $50 years CA vs. AA P = 0.09.
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An analysis of the distribution of the risk factors 
  associated  with  a  higher  likelihood  of  develop-
ment of TNBC shows an increased prevalence of 
these risk factors among the AA women in the gen-
eral    population  compared  to  white  women.20  As 
opposed  to  luminal  breast  cancer,  increased  par-
ity, and a younger age at first full term pregnancy 
are   associated with an increased risk of develop-
ing TNBC. AA women were also more likely to 
never have breast fed, and reported a shorter dura-
tion of breast feeding per child than white women, 
which are also factors associated with the risk of 
  developing TNBC.
There are few reported studies that specifically 
address the issue of race and survival for women with 
TNBC. Bauer et al13 and Lund et al14 have reported 
a worse survival for AA women overall with breast 
  cancer and within the triple negative subtype, after 
  controlling  for  socioeconomic  factors,  treatment 
delay and tumor characteristics. A recent report, by 
Dawood et al of four hundred and   seventy one patients 
with  TNBC  treated  with    standard  neo-  adjuvant 
  chemotherapy  at  the  MD Anderson  Cancer  Cen-
ter found no detriment in survival or likelihood of 
attaining a pathological complete   remission (pCR) 
  associated with AA race.15 The authors   suggested 
that  treatment  disparities  might  have  resulted  in 
poorer  survival  for  AA  women  with  TNBC  in 
the  other  reported    datasets,  while  their  cohort  of 
1.0
0.8
0.6
0.4
0.2
0.0
0 2 5
AA <50 AA ≥ 50 CA ≥ 50 CA <50
50 75 100 125
BCCSS Months
S
u
r
v
i
v
a
l
 
p
r
o
b
a
b
i
l
i
t
y
Figure 3b. Age adjusted BCSS by race. Age , 50 years CA vs. AA P = 0.37; $50 years CA vs. AA P = 0.01
Table 4. Multiple variable cox proportional hazard models.*
event free survival
Variable HR P-value
Stage 8.34 ,0.0001
XRT 3.09 0.0031
Menopausal status 2.33 0.0287
Race 0.62 0.29
Breast cancer specific survival
Stage 6.82 0.0008
Race 0.36 0.18
*The final models reflect only the variables retained by the process of 
step-wise selection, from among the variables which met the significance 
level for inclusion in univariate modeling.
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irrespective of race. The odds of survival, in fact, 
tended to be more favorable for AA race   compared 
to white and other races. The 3 year relapse free and 
overall survival rates however were low (63% and 
71% respectively) for the entire cohort, independent 
of race. However, in another report, among a smaller 
cohort of 38 TNBC patients treated with standard 
anthracycline and   taxane based neoadjuvant therapy, 
AA race was associated with a lower pCR rate and 
a worse survival probability compared to white and 
other races.21 All the above studies have differences 
in methodology, sample size and the   variables ana-
lyzed. Thus, a direct   comparison of these results with 
our data is not likely to be meaningful.   However, we 
would like to point out similarities and differences 
between the cohort from our institution and the other 
reported datasets.
Our cohort of TNBC patients is unique in that 
the  majority  of  our  cohort  is  comprised  of AA 
women  (71%  as  compared  to  21%  in  the  report 
by Dawood et al 24% in the series by Lund et al 
40% in the dataset from Carey et al and 10% in 
the   California cancer registry study by Bauer et al). 
This is   representative of our overall breast cancer 
population at UTCI. Of the 200 new breast can-
cer  patients  seen  over  the  last  18  months,  60% 
were  AA.  Unlike  the  population  based  cohorts 
reported by Lund et al14 and Carey et al1 but simi-
lar to the single institution study by Dawood et al 
our cohort is comprised entirely of patients with 
  triple negative tumors for whom detailed staging 
and  treatment  history  is  available.  In  our  study, 
stage  at  presentation  did  not  differ  between  the 
two  races  though  numerically  more AA  patients 
presented with node positive disease at   diagnosis 
compared to the   Caucasian patients(53% vs. 36% 
  respectively, P = 0.11). There was no difference in 
the likelihood of   receiving   adjuvant   chemotherapy 
and  radiotherapy  or  the  duration  and  type  of 
  chemotherapy  received  by  race.  Unlike  the  MD 
Anderson study, controlling for these among other 
factors still resulted in a trend towards   better sur-
vival for the Caucasian patients compared to the 
AA patients (HR 0.62 for EFS, and 0.36 for BCSS). 
A longer follow up is needed to see if these dif-
ferences become   statistically significant over time. 
Our results   suggest that treatment disparity alone 
doesn’t  account  for  the  observed    differences  in 
survival between the two races. The cohort from 
MD Anderson may also represent a select group 
of  patients  referred  from  different  geographic 
areas with a different socioeconomic background 
and  baseline  risk  factors  than  our  patients.  Our 
cohort represents a geographically uniform group 
treated at an urban cancer center in the Memphis 
  metropolitan area with a sizeable African   American 
patient  population.  Our  findings  are  significant 
in this regard that our patients are more likely to 
represent the AA women with TNBC in the com-
munity  and  the  survival  disadvantage  that  these 
women face likely represents a complex interplay 
between genetics and their unique socioeconomic, 
cultural and environmental risks.
An  interesting  observation  in  our  cohort  is  the 
age and menopausal status of our patients, with 65% 
being postmenopausal and over half of the patients 
being $age 50 at diagnosis, contrary to the previously 
observed associations between TNBC and younger 
age and premenopausal status.13,22
In addition, we found that AA race was significantly 
associated with a worse BCSS for those patients $50 
years at diagnosis. The significance of this observa-
tion is not entirely clear at this time, but merits   further 
investigation  to  understand  the  unique  hormonal 
milieu that can influence the risk of development and 
outcomes from particular subtypes of breast cancer in 
different age and race groups.
A  range  of  molecularly  heterogeneous  tumors 
sharing a common phenotype, the so called TNBC, 
may account for differences seen in clinical outcomes 
between subsets of patients. Recent molecular char-
acterization of this phenotype has led to interesting 
insights into the biology of these complex tumors and 
some  potential  targets  for  treatment.23  Beyond  the 
tumor itself, racial differences in outcomes can stem 
from  varying  tumor-host  interactions,24  and  phar-
macogenomic differences in efficacy and toxicity of 
  systemic therapies.25–27
The pattern of relapse noted in our study is also 
in  keeping  with  other  reports  of  a  propensity  for 
  systemic relapses for patients with TNBC compared 
to the luminal subtypes.28,29 Overall, 62% of all first 
relapses in our cohort were systemic relapses, with 
no  difference  noted  between  the  two  races.  Thus, 
  better systemic therapies are needed for TNBC that 
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overall survival for these patients.
Advances  in  the  understanding  of  the  biology 
of  these  tumors  and  the  tumor  microenvironment 
are  already  being  translated  into  clinical  practice. 
Encouraging  results  have  been  seen  with  the  first 
in-class  PARP  (poly  ADP-ribose  polymerase-1) 
inhibitor drugs for patients with TNBC30 and those 
with  genetic  mutations  in  the  DNA  repair  genes 
BRCA-1 and 2.31 Several other compounds like the 
CHK1 and AURKB inhibitors, and inhibitors of the 
VEGF, EGFR and IGF pathways are currently under 
investigation for the treatment of TNBC and offer 
hope for the future.
conclusion
In conclusion, our study adds to the growing body of 
literature examining differences in outcomes within 
the  broad  category  of  tumors  classified  as    triple 
  negative. We acknowledge that there are   limitations 
to  our  study,  given  its  retrospective  nature  and  a 
  relatively small sample size. However, our findings 
support the need for molecular sub-classification, and 
search for effective targeted therapies for TNBC.
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